• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 25, 2017

View Archived Issues

Samsung wins first U.S. biosimilar approval as FDA clears Renflexis

HONG KONG – Samsung Bioepis Co. Ltd.'s biosimilar Renflexis (infliximab-abda) will be the first product of the conglomerate's biologics arm to be marketed in the U.S. and only the second infliximab biosimilar in the market after Pfizer Inc.'s Inflectra. Samsung Bioepis gained FDA approval late Friday for its BLA for Renflexis (formerly SB2), a biosimilar candidate referencing Remicade (infliximab, Janssen Biotech Inc.). Read More

News from ECCMID

Polyphor Ltd., of Allschwil, Switzerland, presented data for its OMPTA (outer membrane protein targeting antibiotics) platform, showing a 91 percent clinical cure rate and 9 percent mortality rate in 12 patients treated with lead OMPTA murepavadin, with multiple doses of the drug demonstrating acceptable tolerability. Read More

News from AAN

Alder Biopharmaceuticals Inc., of Bothell, Wash., presented data for eptinezumab (formerly ALD-403), which is in phase III development for the prevention of migraine, showing that the drug was designed to be delivered intravenously and target soluble CGRP ligand with high selectivity and affinity as characterized by a rapid on-rate and very slow off-rate. Read More

In the clinic

Vyome Biosciences Pvt Ltd., of New Delhi, India, said it completed enrollment in its proof-of-concept study of VB-1953, a topically administered gel, for patients with moderate to severe acne. Data are expected later this year. Read More

Early diagnosis good, but good targets are better in Alzheimer's

BOSTON – At the presidential plenary session of the 2017 annual meeting of the American Academy of Neurology, Ronald Petersen freely admitted that "I'm biased." Read More

Albireo preps phase III plans for rare pediatric liver disease drug

AMSTERDAM – New data on Albireo Pharma Inc.'s A-4250, an ileal bile acid transport inhibitor, has shown its capacity to reduce high levels of serum bile acids (sBA), which are often associated with severe itching, or pruritus, and liver damage in children with the rare cholestatic liver disease progressive familial intrahepatic cholestasis (PFIC). Read More

Bristol-Myers NASH drug reduces liver fat in phase II trial

AMSTERDAM – Bristol-Myers Squibb Co.'s lead nonalcoholic steatohepatitis (NASH) candidate, BMS-986036, significantly reduced liver fat vs. placebo, meeting the primary endpoint of a phase II trial, the company reported during the International Liver Conference. Read More

NGM Bio touts liver fat reductions in phase II

AMSTERDAM – NGM Biopharmaceuticals Inc., true to its fascination with the long-lasting effects of gastric bypass surgery and what President Jeff Jonker called the procedure's "fundamental rewiring" of metabolism, honed in on the liver de-fatting feats of its lead candidate, NGM282, during a presentation at the International Liver Conference. Read More

Industry: FDA unduly dour regarding value of off-label communication

The docket for the FDA's most recent efforts to address the off-label question drew dozens of comments, many of which were at least modestly supportive of the changes in the agency's stance. However, two trade associations opined that the FDA is too pessimistic about the impact of a less stringent standard for off-label communication on the incentives to study those off-label uses. Read More

Regulatory front

The FDA is issuing draft guidance to aid government public health and emergency response stakeholders in testing to extend the shelf life of doxycycline tablets and capsules kept in strategic stockpiles in the event of an anthrax emergency. Read More

Financings

Galapagos NV, of Mechelen, Belgium, said it closed its underwritten public offering of 4.3 million American depositary shares (ADSs), which included the full exercise of the underwriters' option to purchase additional ADSs, at $90 each, for gross proceeds of $395.2 million. Read More

Other news to note

Hitgen Ltd., of Chengdu, China, said it inked a collaborative agreement with the Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr), to focus on oncology, regenerative medicine and virology. Hitgen will utilize its technology platform to identify new small-molecule leads for therapeutic targets identified by the collaboration. TSRI and Calibr will provide target materials and expertise to prosecute drug targets of interest. Read More

News from EASL

Arrowhead Pharmaceuticals Inc., of Pasadena, Calif., said data from a phase Ia/Ib study of ARC-AAT, an earlier generation of the company's RNAI candidate for the treatment of liver disease associated with alpha-1 antitrypsin (AAT) deficiency, can achieve "deep durable and dose-dependent reductions" of AAT, with the highest dose studied in healthy volunteers achieving near full suppression of the liver production of the AAT protein. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe